Health & coverage · Breast cancer
If you’ve been through breast cancer, you’ve already faced harder questions than any application will ask. Underwriting comes down to four things: how long since your last treatment, whether it reached the lymph nodes or came back, which medications you still take — and which carrier you ask. During treatment, guaranteed acceptance stays open. Here’s the honest map.
The honest landscape
Most final expense carriers start the clock when treatment ends, not at diagnosis — and a few publish breast cancer by name. Transamerica’s FE Express guide gives it its own row: under two years since last treatment is a decline, two to four years reaches its Select class, and four or more years its best Premier class (Premier isn’t offered in California). Corebridge’s SimpliNow Legacy guide lists Stage 1 breast cancer diagnosed or treated within the last 48 months for its level plan, and Stage II within 48 months for its graded plan. Elsewhere the general cancer clocks apply: United Home Life reaches its Premier plan at two years cancer-free, Mutual of Omaha’s Living Promise grades two to four years out and goes Level after four (per FMO-published grids), and Royal Neighbors grades two to five years and offers Standard after five.
Hormone therapy is the question most survivors don’t see coming. Years of tamoxifen or an aromatase inhibitor — anastrozole (Arimidex), letrozole (Femara), exemestane (Aromasin) — show up on every prescription check, and carriers read them in opposite ways. Mutual of Omaha lists Arimidex and tamoxifen as “additional information” drugs for Living Promise rather than automatic knockouts, though the same pills rule out its Term Life Express. United Home Life’s guide says breast-cancer maintenance or preventative medications are OK for consideration. American Amicable’s Senior Choice rates tamoxifen, Arimidex, and Femara by fill date. And Aetna’s published drug list marks anastrozole, letrozole, exemestane, fulvestrant, Ibrance, and Verzenio unacceptable on all three Accendo plans.
The lines that don’t move with time are spread and recurrence. Transamerica declines cancer that reached the lymph nodes or other organs, came back, or occurred at multiple sites — on both its Immediate Solution and FE Express products, with no clock that clears it. Royal Neighbors routes more than one cancer occurrence to guaranteed issue only; American Amicable’s Senior Choice routes it to its return-of-premium plan instead. And beneath every one of these sits the honest floor: guaranteed-issue whole life asks nothing. Mutual of Omaha’s runs to age 85, Corebridge’s and Americo’s to 80 — with a graded period for natural-cause death in the first two years (three at Americo) and full accidental coverage from day one.
Your realistic paths
Transamerica FE Express Select at 2–4 years and Premier at 4+; United Home Life Premier at 2 years cancer-free; Mutual of Omaha Level after 4; Royal Neighbors Standard after 5. Corebridge lists Stage 1 within 48 months for its level plan.
Mutual of Omaha (2–4 years), Royal Neighbors (2–5 years), United Home Life (12–24 months cancer-free), and American Amicable (cancer or cancer medication within 3 years): permanent coverage with a limited benefit early on, then full.
No health questions — chemo, radiation, recurrence, anything. Mutual of Omaha to 85, Corebridge and Americo to 80. Graded period for natural causes; accidents covered in full from day one.
What moves the needle
Transamerica counts from your last treatment and Royal Neighbors from treatment completed — not from diagnosis. Have your final surgery, chemo, or radiation date handy when you apply.
Tamoxifen or Arimidex doesn’t automatically disqualify at Mutual of Omaha’s Living Promise or United Home Life, while Aetna’s Accendo plans list aromatase inhibitors as unacceptable. Same prescription, opposite answers.
Transamerica declines any history of spread to the lymph nodes; Corebridge separates Stage 1 (level plan) from Stage II (graded). Your pathology report quietly decides which doors open.
Inside the application
Where the doors are
Every carrier draws its lines differently — these documented niches are why we shop your exact situation instead of accepting the first answer. Sources labeled; guidelines change without notice.
FE Express gives breast cancer its own row: Select 2–4 years after last treatment, Premier at 4+ — when treatment is complete with no lymph-node spread and no recurrence. Any spread, recurrence, or second cancer is a decline on both of its final expense products.
Our full Transamerica reviewArimidex and tamoxifen sit on Living Promise’s “additional information” drug list rather than its not-eligible list — current use doesn’t automatically disqualify; your cancer history decides Level or Graded. The same drugs rule out Term Life Express.
Our full Mutual of Omaha reviewIts 2026 guide notes breast-cancer maintenance or preventative medications are OK for consideration. Cancer-free 12–24 months routes to its graded Express Issue plan; 2+ years reaches Premier, and 5+ years opens its term plans too.
The SimpliNow Legacy training guide lists Stage 1 breast cancer diagnosed or treated within the last 48 months for its level plan, and Stage II within 48 months for graded (ages 50–80). It’s a 2021 guide — we confirm current rules before quoting.
Our full AIG (Corebridge) reviewSenior Choice (ages 50–85) rates tamoxifen, Arimidex, and Femara by fill date: within 2 years routes to the return-of-premium plan, within 3 to Graded, older to Immediate. A second lifetime cancer routes to return-of-premium rather than a decline.
Our full American Amicable reviewThe caution flag: its published drug list (2020 edition) marks anastrozole, letrozole, exemestane, fulvestrant, Ibrance, and Verzenio unacceptable on all three Accendo plans. If you’re still taking one, we look elsewhere first.
Our full Aetna (Accendo) reviewStraight answers
Often, yes — but the carrier matters more than usual. Mutual of Omaha’s Living Promise lists Arimidex and tamoxifen as additional-information drugs rather than knockouts, United Home Life calls maintenance breast-cancer medications OK for consideration, and American Amicable’s Senior Choice rates them by fill date. Aetna’s Accendo plans and Mutual of Omaha’s term product list them as unacceptable. That split is exactly why we check your medication list before you apply anywhere.
Not everywhere. Transamerica declines any history of spread to the lymph nodes on both of its final expense products, with no waiting period that clears it. The other guides we reviewed key on time since treatment, recurrence, and — at Corebridge — stage, rather than naming lymph nodes. And guaranteed-issue whole life asks no health questions at all: ages 45–85 with Mutual of Omaha, with a graded period for natural causes and accidental death covered in full from day one.
It depends on the carrier’s clock, which usually runs from your last treatment: two years for Transamerica FE Express’s Select class and United Home Life’s Premier plan, four for Mutual of Omaha’s Level plan and Transamerica’s Premier class, five for Royal Neighbors’ Standard tier. Corebridge’s guide is the outlier — it lists Stage 1 breast cancer within the last 48 months for its level plan. A recurrence changes the answer at every carrier.
Yes, but simplified-issue term uses much longer clocks. American Amicable’s Easy Term looks for 8 years since surgery, diagnosis, or last treatment with no recurrence, and Foresters’ non-medical term wants treatment completed more than 10 years ago with no recurrence or recommended treatment — and both exclude recent or current tamoxifen, Arimidex, and Femara on those products. Fully underwritten coverage is individual: Foresters postpones at least a year after treatment, and Mutual of Omaha’s guide generally postpones two to five years.
Usually it’s better to finish the test and get results. Pending tests are their own question: NewBridge treats a recommended diagnostic test you haven’t completed (routine screening excluded) as not eligible, Transamerica FE Express declines pending tests or results, Royal Neighbors routes pending evaluation to guaranteed issue only, and American Amicable’s Senior Choice routes it to its return-of-premium plan. If you want something in place regardless, guaranteed issue asks nothing.
One search, every door
A few basic questions — age, state, and your honest health picture — are exactly what lets us quote you accurately across the whole panel. A decline somewhere else is the start of our search, not the end. No exam to look, no spam, no pressure.
